Skerjanec Simona 4

What Happened
Simona Skerjanec, a director of Atrium Therapeutics, was granted 20,000 equity awards (reported as a derivative award) on February 27, 2026. The filing shows a price of $0.00 and total reported value of $0 at grant — this reflects a compensation award (transaction code "A"), not a cash purchase or sale.

Key Details

• Transaction date: 2026-02-27 (reported on Form 4 filed 2026-03-02). Filing appears timely.
• Transaction type/code: Award/Grant (A) of 20,000 derivative shares; reported price per share = $0.00; reported total value = $0.
• Vesting: The award vests in equal monthly installments over the three years following the grant date, subject to continuous service. (Footnote F1)
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Insider role: Director (not listed as a 10% owner or executive in this summary).

Context
This was a compensation grant (equity award) rather than an open-market purchase or sale. Such grants are common for board compensation and do not involve immediate cash outlay; the awards become economically meaningful only as they vest and/or are exercised according to plan terms. The filing does not indicate any immediate sale or cashless exercise.